Roche Will Pay Zymeworks $55 Million Upfront For Rights To Lung Cancer Drug ZW209
Zymeworks could collect up to $718 million more in milestones, plus royalties, if the deal clears U.S. antitrust review.
Roche agreed to pay Zymeworks a $55.0 million upfront for exclusive worldwide rights to ZW209, an experimental cancer drug aimed at the DLL3 protein, according to an 8-K the company filed Friday. Zymeworks, a biotechnology company that develops antibody-based medicines and manages a portfolio of licensed healthcare assets, signed the agreement Thursday.
Up to $718 million in milestones
The upfront payment is non-refundable and comes due after the deal clears review under the Hart-Scott-Rodino antitrust law. Roche will also pay a further $40.0 million when it starts the Phase Ib trial, the next stage of testing, for the first product.
Zymeworks is eligible for as much as $718 million in research, development, commercial and sales-based milestones. It would also receive tiered royalties from the high single digits to the mid-teens as a percentage of annual net sales.
Royalties run product by product and country by country until the later of 10 years after first commercial sale or the expiry of the last valid licensed patent claim. The company's press release said the covered patents extend into the 2040s.
Who runs the trials
ZW209 is a trispecific T cell engager, a drug built to steer the body's immune cells toward DLL3-bearing tumor cells. Zymeworks will run the Phase Ia monotherapy dose-escalation trial at Roche's expense, and the company said the FDA has cleared its investigational application. The study will enroll adults with select advanced solid tumors, including small cell lung cancer.
Roche takes sole responsibility, and bears the cost, for all development after that, along with manufacturing and sales. It must use commercially reasonable efforts to develop and sell one product in one indication in the United States.
Zymeworks keeps ownership of the know-how and patents on ZW209's composition of matter and of its Azymetric, EFECT and TriTCE Co-stim platforms. Roche can terminate at any time, at its sole discretion, with written notice.
A DLL3 non-compete and an antitrust gate
The license takes effect on the first business day after antitrust clearance. From then until the earliest of five years, Roche's first Phase 3 study start or termination, Zymeworks cannot do its own work on DLL3-targeting T-cell engagers, or license them to others, outside the deal.
Adam Schayowitz, Zymeworks' executive vice president and head of R&D, said the agreement reflects a strategy of partnering selected assets in ways that "share development risk while preserving meaningful participation in their future success."
Zymeworks shares closed at $28.44 on Thursday, up 1.16%, before the announcement.
Zymeworks management will discuss the deal on a conference call on October 27 at 8:30 a.m. ET.